<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43596">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980225</url>
  </required_header>
  <id_info>
    <org_study_id>VanLanduyt2013</org_study_id>
    <nct_id>NCT01980225</nct_id>
  </id_info>
  <brief_title>Implantation Rate of Vitrified-warmed Collapsed Blastocysts</brief_title>
  <official_title>Randomized Controlled Trial Comparing the Implantation Rate of Vitrified-warmed Blastocysts With and Without Artificial Shrinkage Before Vitrification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Reproductive Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Reproductive Medicine, Belgium</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our centre, the implantation rate of frozen blastocysts (cryopreserved using
      vitrification)was 20,3% (Van Landuyt et al. 2011).  This implantation rate is lower when
      compared to data from other observational studies. Retrospective studies have shown that
      artificial shrinkage of the blastocoelic cavity (also called collapse) and dehydration of
      the blastocyst just before vitrification can have a positive effect on the survival after
      warming. This collapse can be induced by using a laser.  The study of Iwayama et al. 2010
      has shown a similar survival rate but an increase in the implantation rate of collapsed
      blastocysts compared to non-collapsed blastocysts.

      The aim of the study is to investigate the effect of artificial shrinkage by laser-induced
      collapse on the implantation potential of vitrified-warmed day 5 or day 6 blastocyst stage
      embryos in a prospective randomised controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>implantation rate of the embryo in the first frozen transfer cycle</measure>
    <time_frame>approximately 10 weeks after the first frozen embryo transfer</time_frame>
    <safety_issue>No</safety_issue>
    <description>patients are enrolled in the study at oocyte retrieval. When patient is not pregnant after fresh embryo transfer, she comes back to use the frozen embryos at least one month after the initial inclusion. After the frozen embryo transfer, poshCG is measured 14 days after transfer. Approximately 10 weeks after transfer, implantation rate of the frozen embryos is assessed. This is the number of intra-uterine gestational sacs seen on ultrasound on the number of embryos transferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival rate of warmed blastocysts</measure>
    <time_frame>0-30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>this is the morphological assessment of survival of the blastocyst after warming</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate per warmed blastocyst</measure>
    <time_frame>approximately 10 weeks after first frozen transfer</time_frame>
    <safety_issue>No</safety_issue>
    <description>implantation rate of the transferred embryo per embryo initially warmed in that frozen transfer cycle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Implantation Rate of Vitrified Blastocysts</condition>
  <arm_group>
    <arm_group_label>Collapse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This control arm includes the patients of which the blastocysts are vitrified without performing collapse</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collapse</intervention_name>
    <description>inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified</description>
    <arm_group_label>Collapse</arm_group_label>
    <other_name>artificial shrinkage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female age &lt;39 years

          -  at least 1 blastocyst available for cryopreservation

        Exclusion Criteria:

          -  sperm origin: testicular or epididymal sperm extraction

          -  IVM (in-vitro maturation) cycles

          -  PGD cycles (preimplantation genetic diagnosis)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisbet Van Landuyt, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Reproductive Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisbet Van Landuyt, MSc</last_name>
    <phone>+32 2 477 4028</phone>
    <email>lisbet.vanlanduyt@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Greta Verheyen, PhD</last_name>
    <phone>+32 24776690</phone>
    <email>greta.verheyen@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Reproductive Medicine</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbet Van Landuyt, MSc</last_name>
      <phone>+32 2 477 4028</phone>
      <email>lisbet.vanlanduyt@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Lisbet Van Landuyt, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Reproductive Medicine, Belgium</investigator_affiliation>
    <investigator_full_name>Lisbet Van Landuyt</investigator_full_name>
    <investigator_title>klinisch embryoloog</investigator_title>
  </responsible_party>
  <keyword>vitrification, blastocyst, artificial shrinkage, collapse</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
